bluebird bio to Present at the Leerink Swann 2012 Global Healthcare Conference
February 09, 2012 08:03 AM Eastern Time
CAMBRIDGE, Mass.--(EON: Enhanced Online News)--bluebird bio, a leader in the development of innovative gene therapies for severe genetic disorders, announced today that Nick Leschly, chief executive officer, is scheduled to present at the Leerink Swann 2012 Global Healthcare Conference on Wednesday, February 15, 2012 at 2:15PM EST at the Waldorf Astoria Hotel in New York City.
Mr. Leschly is expected to discuss the company’s vision for developing gene therapies for genetic diseases with high unmet medical needs, including beta-thalassemia, sickle cell disease and childhood cerebral adrenoleukodystrophy (CCALD). The presentation will include updates on the launch of the company’s pivotal CCALD clinical trial, as well as patient data updates and enrollment of the ongoing beta-thalassemia/sickle cell disease trial.